Results 11 to 20 of about 5,480 (216)

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis. [PDF]

Int J Rheum Dis
ABSTRACT Objective Acute anterior uveitis (AAU) is the most common extra‐musculoskeletal manifestation of axial spondyloarthritis (axSpA). This study compared the effect of the tumor necrosis factor inhibitor (TNFi) certolizumab pegol (CZP) with standard non‐biologic care, on AAU flare rate in patients with axSpA and high risk of recurrent uveitis ...
Haroon N, Baskurt Z, Chim T, Inman RD, Kumke T, Tham R, Kim M, van der Horst-Bruinsma I, Gensler LS.   +8 more
europepmc   +2 more sources

The Impact of Nonsteroidal Anti-Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10-Year Results From an Inception Cohort. [PDF]

Arthritis Rheumatol
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Torgutalp M, Rios Rodriguez V, Proft F, Protopopov M, Rademacher J, Haibel H, Sieper J, Rudwaleit M, Poddubnyy D.   +8 more
europepmc   +2 more sources

Water Fraction Ratio of the Sacroiliac Joint Subchondral Bone Marrow in Patients with Ankylosing Spondylitis Predicts the Degree of Disease Activity

Diagnostics, 2022
Objectives: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis with characteristic involvement of the spine and sacroiliac joints. MRI may be the only indicator of disease activity or response.
Beum Jin Kim, Young Han Lee, Joohee Lee, Sungjun Kim, Ho-Taek Song   +4 more
doaj   +1 more source

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI

RMD Open, 2020
Objectives To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying ...
Sofia Ramiro, Elsa Vieira-Sousa, Alexandre Sepriano, Helena Santos, Jose Marona, Santiago Rodrigues-Manica, Fernando Pimentel-Santos, Ana Filipa Mourão, Nélia Gouveia, Jaime Cunha Branco, Filipe Vinagre, João Tavares-Costa, João Rovisco, Miguel Bernardes, Nathalie Madeira, Rita Cruz-Machado, Raquel Roque, Joana Leite Silva, Mary Lucy Marques, Raquel Miriam Ferreira   +19 more
doaj   +1 more source

Estimation of disease activity in patients with ankylosing spondylitis in the real practice of a rheumatologist in Russia (Part 2)

Научно-практическая ревматология, 2012
Objective: to compare different methods for estimating ankylosing spondylitis (AS) activity in the real practice of a rheumatologist in the Russian Federation. Subjects and methods.
Evgeny Vladimirovich Volnukhin, E A Galushko, A G Bochkova, A V Smirnov, Sh F Erdes   +4 more
doaj   +1 more source

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR

Arthritis Research & Therapy, 2021
Background Limited information is available on the impact of treatment with a tumor necrosis factor inhibitor (TNFi) on structural lesions in patients with recent-onset axial spondyloarthritis (axSpA).
Walter P. Maksymowych, Pascal Claudepierre, Manouk de Hooge, Robert G. Lambert, Robert Landewé, Anna Molto, Désirée van der Heijde, Jack F. Bukowski, Heather Jones, Ron Pedersen, Annette Szumski, Bonnie Vlahos, Maxime Dougados   +12 more
doaj   +1 more source

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]

, 2015
Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi, Braun, Jürgen, Bukowski, Jack F, Citera, Gustavo, Dougados, Maxime, Jones, Heather, Kotak, Sameer, Logeart, Isabelle, Maksymowych, Walter P, Marshall, Lisa, Pedersen, Ron, Sieper, Joachim, Van den Bosch, Filip, van der Heijde, Désirée, Vlahos, Bonnie, Wajdula, Joseph   +15 more
core   +1 more source

GUIDELINES FOR THE ASSESSMENT OF DISEASE ACTIVITY AND FUNCTIONAL STATUS IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN CLINICAL PRACTICE

Научно-практическая ревматология, 2017
The paper gives the recommendations for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice, which have been developed by experts, by taking into account international and Russian ...
T. V. Dubinina, I. Z. Gaidukova, A. A. Godzenko, S. A. Lapshina, A. P. Rebrov, O. A. Rumyantseva, V. V. Badokin, A. G. Bochkova, O. V. Bugrova, A. I. Dubikov, O. N. Ivanova, T. V. Korotaeva, O. B. Nesmeyanova, I. P. Nikishina, E. N. Otteva, T. A. Raskina, A. V. Smirnov, A. V. Sitalo, Sh. F. Erdes   +18 more
doaj   +1 more source

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?

Arthritis Research & Therapy, 2020
Background To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to the second TNFi in axial spondyloarthritis (axSpA).
Santiago Rodrigues Manica, Alexandre Sepriano, Fernando Pimentel-Santos, Nélia Gouveia, Anabela Barcelos, Jaime C. Branco, Miguel Bernardes, Raquel Miriam Ferreira, Elsa Vieira-Sousa, Sofia Barreira, Filipe Vinagre, Raquel Roque, Helena Santos, Nathalie Madeira, João Rovisco, Alexandra Daniel, Sofia Ramiro   +16 more
doaj   +1 more source

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels

ACR Open Rheumatology, 2021
Objective Biological agents have shown markedly different response rates by baseline C‐reactive protein (CRP). Here, we determine the response of patients with nonradiographic axial spondyloarthritis (nr‐axSpA) to etanercept stratified by their baseline ...
Hoi Ki Joshua Tam, Peter Nash, Philip C. Robinson   +2 more
doaj   +1 more source